

Coronary Slow Flow Phenomenon - Adding Myocardial Fibrosis to the Equation

Filipe Penna de Carvalho^{1,2} and Clério Francisco de Azevedo^{1,3}

Diagnósticos da América SA,¹ Rio de Janeiro, RJ - Brazil

Américas Serviços Médicos,² Rio de Janeiro, RJ - Brazil

Duke University Hospital - Medicine/Cardiology,³ Durham, North Carolina - USA

Short Editorial related to the article: *Determination of Myocardial Scar Tissue in Coronary Slow Flow Phenomenon and The Relationship Between Amount of Scar Tissue and Nt-ProBnpBNP*

Initially described more than 40 years ago by Tambe et al.,¹ coronary slow flow phenomenon (CSFP) is characterized by delayed contrast medium progression in the absence of obstructive coronary epicardial disease during invasive coronary angiography.² CSFP typically affects young male smokers, who often presents with acute coronary syndrome (ACS) or recurrent refractory resting angina requiring hospital admission.²⁻⁴ Moreover, life-threatening arrhythmias and sudden cardiac death have also been associated with CSFP.⁵

Despite increased awareness and research, CSFP remains an elusive and poorly understood condition, with many proposed pathogenic mechanisms including endothelial, vasomotor and microvascular dysfunction.^{2,6} Indeed, an abnormal regulation of microvascular tone that occurs only during resting conditions, while coronary flow reserve is within normal range, has been described in CSFP.⁷

In this issue of *Arquivos Brasileiros de Cardiologia*, Candemir et al.,⁸ add an important contribution to this field of knowledge. The authors studied 35 patients with chest pain referred for a diagnostic invasive coronary angiography (ICA). All had negative troponin levels and no evidence of ischemia on exercise stress testing. A comparison was made between patients who presented with CSFP in the left anterior descendant artery (n=19) and matched controls with normal coronary arteries and no coronary flow abnormalities (n = 16). They sought to investigate if myocardial scarring identified using cardiac magnetic resonance imaging (CMR) and/or if N-terminal Pro B-type Natriuretic Peptide (NT-Pro-BNP) levels elevation were more frequent in the CSFP group. Importantly, to the best of our knowledge, this was the first study to use CMR to evaluate the presence of myocardial fibrosis in the CSFP population.

Noteworthy, CMR using the delayed enhancement (or late gadolinium enhancement) technique is now a widely available and a powerful tool that allows the precise identification and

quantification of myocardial fibrosis, with multiple studies demonstrating its utility in the diagnosis and prognosis of both ischemic and non-ischemic cardiomyopathies.⁹⁻¹⁵ Interestingly, the authors demonstrate that delayed enhancement was present in up to 52.5% (n = 10) of the patients with CSFP as opposed to none in the control group. The authors thus concluded that CSFP may result in irreversible changes in the myocardial tissue.

However, we do not believe the presented data can be used to establish causality between CSFP and myocardial fibrosis. For instance, in a subset of patients (n = 3) the myocardial injury was seen in the inferior and inferolateral walls, and not in the typical left anterior descendant coronary artery territory where CSFP was present. Moreover, the authors do not describe whether the delayed enhancement pattern observed in their study was predominantly ischemic (e.g., subendocardial or transmural) or non-ischemic (midwall or epicardial). Most importantly, as the authors point out during the discussion, they performed a transversal study and, thus, no temporal relationship between CSFP and myocardial fibrosis can be established. One of the many possible explanations is that these patients with myocardial fibrosis by CMR might have previously presented with a myocardial infarction with normal coronary arteries (MINOCA) and the CSFP is but a consequence of this previous event. Although the authors did find an association between CSFP and myocardial fibrosis, we believe that further research is needed to determine whether there is a causal relationship between them.

Interestingly, higher NT-pro-BNP levels, a well-known marker of prognosis in ACS,¹⁶ were also seen in patients with CSFP when myocardial scarring was detected by CMR, as compared to CSFP without evidence of fibrosis by CMR (NT-pro-BNP = 147.10 pg/ml vs . 28.0 pg/ml, p = 0,03).

Importantly, in a previously published study by Yurtdaş et al.,⁶ elevated NT-pro-BNP levels were shown to correlate with angina and ST-segment depression in patients with CSFP during exercise treadmill testing. However, no abnormalities were seen during exercise testing in any patient of this study. Again, although the authors demonstrate an association of NT-pro-BNP with CSFP and myocardial fibrosis, we believe that no definitive causal relationship can be established based on the presented data.

Altogether, this an interesting work by Candemir et al.⁸ using CMR to study a still obscure condition. We find it very interesting that CMR allowed the detection of myocardial fibrosis in a subgroup of patients with CSFP without history of prior myocardial infarction. Myocardial scarring identification

Keywords

Heart Failure; Fractional Flow Reserve; Cicatrix; Hypertrophic; Prognosis; Natriuretic-Peptide C-Type; Endomyocardial Fibrosis; Magnetic Resonance Spectroscopy.

Mailing Address: Filipe P. Carvalho •

Centro Integrado de Diagnóstico do Leblon, CDPI Cardiologia – 2º andar – Av. Ataulfo de Paiva, 669. Postal Code 22440-032, Rio de Janeiro, RJ – Brazil
E-mail: filipepenna@me.com

DOI: <https://doi.org/10.36660/abc.20200187>

using delayed enhancement imaging is a powerful prognostic tool in multiple cardiomyopathies, both ischemic and nonischemic. Although small in size, this study by Candemir et al.⁸ opens up new research possibilities to answer whether there is causality in the association between CSFP and myocardial fibrosis and if the presence of myocardial fibrosis in

these patients have any prognostic implication or, for instance, is associated with a higher likelihood of malignant arrhythmias. Conversely, future research using novel CMR techniques for tissue characterization, including T1 and T2 mapping, may also help shed light into this still poorly understood condition.

References

1. Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries—A new angiographic finding. *Am Heart J*. 1972;84(1):66-71.
2. Wang X, Nie S-P. The coronary slow flow phenomenon: characteristics, mechanisms and implications. *Cardiovasc Diagn Ther*. 2011;1(1):37-43.
3. Fineschi M, Gori T. Coronary Slow-Flow Phenomenon or Syndrome Y. *J Am Coll Cardiol*. 2010;56(3):239-40.
4. Beltrame JF, Limaye SB, Horowitz JD. The Coronary Slow Flow Phenomenon – A New Coronary Microvascular Disorder. *Cardiology*. 2002;97(4):197-202.
5. Saya S, Hennebry TA, Lozano P, Lazzara R, Schechter E. Coronary Slow Flow Phenomenon and Risk for Sudden Cardiac Death Due to Ventricular Arrhythmias: A Case Report and Review of Literature. *Clin Cardiol*. 2008;31(8):352-5.
6. Yurtdaş M, Özcan IT, Çamsarı A, Cice KD, Tamer L, Cin VC. NT-pro-BNP levels and their response to exercise in patients with slow coronary flow. *Arq Bras Cardiol*. 2012;99(6):1115-22.
7. Fineschi M, Bravi A, Gori T. The “slow coronary flow” phenomenon: Evidence of preserved coronary flow reserve despite increased resting microvascular resistances. *Int J Cardiol*. 2008;127(3):358-61.
8. Candemir M, Sahinarslan A, Yazol M, Oner YA, Boyaci B. Determinação do tecido cicatricial do miocárdio no fenômeno de fluxo coronário lento e a relação entre quantidade de tecido cicatricial e o Nt-Pro Bnp. *Arq Bras Cardiol*. 2020; 114(3):540-551
9. Sara L, Szarf G, Tachibana A, Shiozaki AA, Villa AV, Oliveira AC, et al. II Diretriz de Ressonância Magnética e Tomografia computadorizada Cardiovascular da Sociedade Brasileira de Cardiologia e do Colégio Brasileiro de Radiologia. *Arq Bras Cardiol*. 2014;103(6):1-86.
10. Wu KC, Kim RJ, Bluemke D, Rochitte CE, Zerhouni EA, Becker LC, et al. Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. *J Am Coll Cardiol*. 1998;32(6):1756-64.
11. Kim HW, Farzaneh-Far A, Kim RJ. Cardiovascular Magnetic Resonance in Patients With Myocardial Infarction. Current and Emerging Applications. *J Am Coll Cardiol*. 2009;55(1):1-16.
12. Azevedo CF, Nigri M, Higuchi ML, Pomerantzeff PMA, Spina G, Sampaio R, et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. *J Am Coll Cardiol*. 2010;56(4):278-87.
13. Azevedo Filho CF de, Hadlich M, Petriz JLF, Mendonça LA, Moll Filho JN, Rochitte CE. Quantificação da massa infartada do ventrículo esquerdo pela ressonância magnética cardíaca: comparação entre a planimetria e o método de escore visual semi-quantitativo. *Arq Bras Cardiol*. 2004;83(2):111-7.
14. Carvalho FP de, Erthal F, Azevedo CF. The Role of Cardiac MR Imaging in the Assessment of Patients with Cardiac Amyloidosis. *Magn Reson Imaging Clin N Am*. 2019;27(3):453-63.
15. de Carvalho FP, Azevedo CF. Comprehensive Assessment of Endomyocardial Fibrosis with Cardiac MRI: Morphology, Function, and Tissue Characterization. *RadioGraphics*. Jan. 2020:190148.
16. Haaf P, Balmelli C, Reichlin T, Twerenbold R, Reiter M, Meissner J, et al. N-terminal Pro B-type Natriuretic Peptide in the Early Evaluation of Suspected Acute Myocardial Infarction. *Am J Med*. 2011;124(8):731-9.

